The fact that small formylated peptides released from bacteria at the site of an infection are functionally active in an environment of low pH and high protease activity suggested to us that our formylated WNT5A-derived hexapeptide (Foxy5) would similarly resist degradation in the tumor microenvironment, a site also likely to have a low pH and elevated protease activity. Here, WNT5A is linked to neoplasm.